Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases.

By D. Kontoyiannis, M. Lionakis, Russell E. Lewis, Georgios Chamilos, M. Healy, Cheryl A. Perego, A. Safdar, H. Kantarjian, R. Champlin, T. Walsh and 1 more. Journal of Infectious Diseases, 2005

675 citations recorded by the source corpus.

Subfields: Infectious Diseases, Ophthalmology, Small Animals

View Paper: https://www.semanticscholar.org/paper/7a5bf23f324dc83313f3f652bee569ddf8666ad3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Infectious Diseases

1. M. Pfaller
2. D. Diekema
3. J. Guinea
4. D. Kontoyiannis
5. Georgios Chamilos
6. M. Arendrup

In Small Animals

1. M. Pfaller
2. D. Diekema
3. J. Guinea
4. D. Kontoyiannis

Citations in the corpus

• Epidemiology of Invasive Mycoses in North America (2010, background): “In the past decade, however; zygomycosis has emerged as an increasingly important mycosis, particularly among HSCT recipients and patients with hematologic malignancies (Kontoyiannis et al. 2005; Marr et al. 2002a; Roden et al. 2005; Siwek et al. 2004).”
• Pathogenesis of mucormycosis. (2012, background): “Although the study did not explore the mechanism by which voriconazole exposure increases virulence of Mucorales, it may provide an explanation for the emergence of mucormycosis in patients with hematologic malignancies who are receiving voriconazole prophylaxis [58–62].”
• ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. (2014, background): “A comparison of morphological versus molecular identification of 19 isolates of Mucorales from patients with mucormycosis showed that identification by morphology was erroneous in >20% of the cases [64].”
• Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. (2006, background): “e64 • CID 2006:42 (1 April) • BRIEF REPORT zygomycosis cases is likely to be associated with the intensive use of immunosuppressive therapies, coupled with the use of antifungal therapies that do not have activity against these fungi [6].”
• Epidemiology and outcome of zygomycosis: a review of 929 reported cases. (2005, neutral): “Sinus Overall 359/929 (39) 165/359 (46) Rhinocerebral 196/929 (21) 122/196 (62) Sino-orbital 74/929 (8) 18/74 (24) Sinusitis 74/929 (8) 12/74 (16) Sinopulmonary 15/929 (2) 13/15 (87) Pulmonary Overall 224/929 (24) 170/224 (76) Localized 121/224 (54) 73/121 (60) Deep extension 15/224 (7) 13/15 (87) D”
• Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. (2008, methodology): “Therefore, because of the lack of a method for the early diagnosis of zygomycosis, riskbased approaches and AMB-based (or, possibly, posaconazolebased) preemptive regimens should be considered for patients who are at a high risk for zygomycosis and who are receiving antifungal agents with no or litt”